Atea Pharmaceuticals, Inc.
AVIRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Atea Pharmaceuticals, Inc. (AVIR) is listed under Biotechnology. With a market capitalization of $388.9M, it sits in small-cap territory. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Market Cap
$388.9M
Beta
0.32
P/E (TTM)
—
P/E (Fwd)
-3.51
EPS (TTM)
$-2.18
EPS (Fwd)
$-1.39
ROE
-52.6%
ROA
-33.5%
Cash
$256.0M
Total Debt
$634,000
Free CF
-$87.7M
52W Change
39.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $256.0M in cash comfortably exceeding the $634K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$87.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -52.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Atea Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AVIR.